LIVINGSTON, N.J.--(BUSINESS WIRE)--Columbia Laboratories, Inc. (NASDAQ: CBRX) today announced it has completed the treatment phase of its pivotal Phase III clinical study of PROCHIEVE® 8% (progesterone gel) to prevent recurrent preterm birth. This 669-patient randomized, double-blind, placebo-controlled clinical trial is the largest preterm prevention study ever conducted. The ultimate goal of this program is to expand the PROCHIEVE 8% label beyond infertility and secondary amenorrhea, for which it is currently FDA-approved and commercially available, to include the prevention of recurrent preterm birth.
